导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.43% | 1882/4773 |
| 近一周 | -1.14% | 348/5462 |
| 近一月 | -1.99% | 1117/5421 |
| 近一季 | -3.82% | 1477/5209 |
| 近半年 | -6.43% | 3083/4920 |
| 近一年 | 4.40% | 1727/4366 |
| 近两年 | 30.64% | 2243/2954 |
| 近三年 | 18.69% | 1522/2253 |
| 成立以来 | 60.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.29% 1582/4961 |
7.99% 2639/5312 |
- - |
- - |
| 2025 | 6.17% 2972/4813 |
-5.10% 3256/3635 |
1.18% 2431/4076 |
10.49% 3285/4524 |
0.08% 2236/4813 |
| 2024 | 16.54% 796/3463 |
5.20% 393/2808 |
2.27% 366/3014 |
8.87% 2718/3129 |
-0.50% 1444/3463 |
| 2023 | 2.33% 322/2656 |
13.16% 277/2280 |
-0.51% 386/2385 |
-4.87% 1242/2515 |
-4.46% 1043/2655 |
| 2022 | -15.36% 418/2207 |
-12.47% 618/1919 |
3.38% 1160/2016 |
-10.09% 345/2113 |
4.02% 602/2208 |
| 2021 | 17.55% 229/1822 |
-0.15% 333/1255 |
4.97% 833/1330 |
9.65% 133/1466 |
2.28% 638/1822 |
| 2020 | 15.72% 780/1250 |
-10.47% 781/1028 |
4.74% 901/1067 |
9.51% 644/1164 |
12.68% 444/1184 |
| 2019 | 9.44% 732/1092 |
16.61% 667/754 |
-7.37% 556/804 |
-1.40% 652/850 |
2.75% 859/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时央企结构调整ETF VS. 长安沪深300非周期A(740101) |